Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: A multicenter experience from Argentina

2014 ◽  
Vol 62 (1) ◽  
pp. 153-157 ◽  
Author(s):  
Ana L. Basquiera ◽  
Silvia Pizzi ◽  
Agustín González Correas ◽  
Pablo G. Longo ◽  
Wanda C. Goldman ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Myelodysplastic Syndromes ◽  
Hematopoietic Stem

scholarly journals Review of Stem-Cell Transplantation for Myelodysplastic Syndromes in Older Patients in the Context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome Emanating From the Centers for Medicare and Medicaid Services

2011 ◽  
Vol 29 (5) ◽  
pp. 566-572 ◽  
Author(s):  
Sergio A. Giralt ◽  
Mary Horowitz ◽  
Daniel Weisdorf ◽  
Corey Cutler
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Myelodysplastic Syndrome ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Myelodysplastic Syndromes ◽  
Older Patients ◽  
The United States ◽  
Hematopoietic Stem

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic stem-cell disorders that result in varying degrees of cytopenia and risk of transformation into acute leukemia. Allogeneic stem-cell transplantation (SCT) is the only known cure for this disease. The treatment is routinely used for younger patients, but only a minority of patients older than the age of 60 undergo this procedure. The overall MDS incidence is 3.3 per 100,000, but the incidence in patients older than age 70 is between 15 and 50 per 100,000. The median age at presentation is 76 years. Medicare-age patients 65 or older represent 80% of the total population receiving an MDS diagnosis. In the United States, one of the obstacles to SCT for older patients with MDS has been lack of third party reimbursement. On August 4, 2010, the Centers for Medicare and Medicaid Services released their Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndrome. This memo states: “Allogeneic HSCT for MDS is covered by Medicare only for beneficiaries with MDS participating in an approved clinical study that meets the criteria below…. ” In this review, we will summarize what is known regarding the role of allogeneic SCT in older patients as well as other elements that should be included within clinical trials that can provide the evidence necessary to demonstrate that allogeneic SCT should be a covered benefit for Medicare beneficiaries.

scholarly journals HSCT FOR MYELODYSPLASTIC SYNDROMES (MDS)

JBMTCT ◽  
2021 ◽  
Vol 4 (1) ◽  
pp. 120-126
Author(s):  
Sociedade Brasileira de TMO SBTMO ◽  
Fernando Barroso Duarte ◽  
Karine Sampaio Nunes Barroso ◽  
Roberto Luiz da Silva ◽  
Livia Andrade Gurgel ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Myelodysplastic Syndromes ◽  
Marrow Transplantation ◽  
Hematopoietic Stem ◽  
Blood And Marrow Transplantation ◽  
Brazilian Society

THE BRAZILIAN SOCIETY FOR BLOOD AND MARROW TRANSPLANTATION (SBTMO) PRESENTS THE BRAZILIAN GUIDELINES ON HEMATOPOIETIC STEM CELL TRANSPLANTATION

scholarly journals Iron Overload in Patients Undergoing Hematopoietic Stem Cell Transplantation

2010 ◽  
Vol 2010 ◽  
pp. 1-12 ◽  
Author(s):  
Vinod Pullarkat
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Iron Overload ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Myelodysplastic Syndromes ◽  
Current Evidence ◽  
Transfusion Therapy ◽  
Hematopoietic Stem

Recipients of hematopoietic stem cell transplantation (HSCT) frequently have iron overload resulting from chronic transfusion therapy for anemia. In some cases, for example, in patients with myelodysplastic syndromes and thalassemia, this can be further exacerbated by increased absorption of iron from the gut as a result of ineffective erythropoiesis. Accumulating evidence has established the negative impact of elevated pretransplantation serum ferritin, a surrogate marker of iron overload, on overall survival and nonrelapse mortality after HSCT. Complications of HSCT associated with iron overload include increased bacterial and fungal infections as well as sinusoidal obstruction syndrome and possibly other regimen-related toxicities. Based on current evidence, particular attention should be paid to prevention and management of iron overload in allogeneic HSCT candidates, especially in patients with thalassemia and myelodysplastic syndromes. The pathophysiology of iron overload in the HSCT patient and optimum strategies to deal with iron overload during and after HSCT require further study.

Sign in / Sign up

Export Citation Format

Share Document